P1 - Poster Session 1
Event Time: | Sunday May 5, 2019 11:30 am to 6:30 pm |
Topic(s): | Research Methodology, Education, and History, Aging, Dementia, Cognitive, and Behavioral Neurology, Autoimmune Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), General Neurology, Headache, Movement Disorders, MS and CNS Inflammatory Disease, Neuro-oncology, Neuro-ophthalmology/Neuro-otology |
Director(s): | |
Description: | |
Completion Message: | |
CME Credits: | 0 |
Core Competencies: |
Start/End Time | Title | Faculty |
---|---|---|
Currently there are no events in the timeline. |
Speaker | Disclosure |
---|
Neuro-Ophthalmology/Neuro-Otology | |||
---|---|---|---|
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Development of Portable Pupillometer for Assessment of Neurological Disease |
Disclosure: Dr. Moss has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with legal firms, Ology education, Springer, Medlink.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Galcanezumab Significantly Reduced Health Care Resource Utilization and Acute Medication Use in Patients with Chronic Migraine: Findings from a Phase 3, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension |
Disclosure: Dr. Joshi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Lilly, Teva, Supernus, Depomed, Promeus.
|
Aging and Dementia: Animal and Cell Models | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Pathological Changes To the Visual System in Alzheimer’s Disease |
Disclosure: Dr. Mistry has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Cerebellar Atrophies in Neuromyelitis Optica Spectrum Disease (NMOSD) patients |
Disclosure: Dr. Souza has nothing to disclose.
|
Antithrombotic Treatment in Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | A Stroke of Bad Luck : Breakthrough Ischaemic Strokes on DOAC Therapy |
Disclosure: Dr. Chan has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Investigating Directionality of Neurodegeneration in vivo in ALS using Multimodal MRI |
Disclosure: Dr. Toh has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Factors Contributing to Quality Of Life in Patients With Epilepsy. |
Disclosure: Dr. Doyle has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Tumors in the cauda equina: a SEER analysis of tumor types and predictors of outcome |
Disclosure: Dr. Das has nothing to disclose.
|
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Optic Nerve Pathology and Visual Functioning in Pediatric Patients with anti-MOG Antibodies |
Disclosure: Dr. Greenberg has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Alexion, Celgene, and EMD Serono. Dr. Greenberg has received research support from CLENE Nanomedicine, Chugai, and Medimmune.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Results from the Long-Term Open Label Extension Phase Analyses of BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia |
Disclosure: Dr. Beiner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. Beiner holds stock and/or stock options in Biohaven Pharmaceuticals which sponsored research in which Dr. Beiner was involved as an investigator. Dr. Beiner holds stock and/or stock options in Biohaven Pharmaceuticals.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Macular Pigment In Multiple Sclerosis |
Disclosure: Dr. Xhepa has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Assessment of the Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects with Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY Study |
Disclosure: Dr. Reuter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting fee, speaking/teaching fee, from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, EliLilly, Medscape, Novartis, StreamMedUp, TEVA Pharmaceuticals. Dr. Reuter has received research support from research grants from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, EliLilly, Medscape, Novartis, StreamMedUp, TEVA Pharmaceuticals.
|
Aging and Dementia: Animal and Cell Models | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | iPSC Model of CHRFAM7A Effect on a7 Nicotinic Acetylcholine Receptor Function in the Human Context |
Disclosure: Dr. Ihnatovych has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Degree of Retinal Nerve Fiber Layer Thinning in Pediatric MOG-associated Optic Neuritis Appears Similar to Pediatric NMO |
Disclosure: Dr. Shukla has nothing to disclose.
|
Antithrombotic Treatment in Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Triglycerides, Creatinine and Body Mass Index are Independent Predictors of Occurrence of Stroke in Patients Adherent with Direct Oral Anticoagulant |
Disclosure: Dr. Zhang has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | The Vitamin D Activator, CYP27B1, is a Novel Muscle Biomarker of ALS Disease Progression |
Disclosure: Dr. Si has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Characterizing Peri-Ictal Mood Changes in Patients with Epilepsy |
Disclosure: Dr. Pahlavan has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | A Meta-Analysis Determining the Prevalence of Treatment-Associated Neurotoxicity in Cancer-Directed Immunotherapy with Antibodies |
Disclosure: Dr. Horta has nothing to disclose.
|
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Neuronal Autoantibodies and Clinical Significance in Stiff-Person Spectrum Disorder |
Disclosure: Dr. Kaneko has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | The impact of ethnicity on the phenotype of a monogenetic disorder: spinocerebellar ataxias type 3 |
Disclosure: Dr. Gan has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Anti-glutamic acid decarboxylase associated neurologic disorders referred from Neuro-ophthalmology and Neurotology: A case series with characterization of vestibulo-ocular function |
Disclosure: Dr. Wang has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab among Patients with Episodic and Chronic Migraine |
Disclosure: Dr. Ruff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Ruff holds stock and/or stock options in Eli Lilly and Company.
|
Aging and Dementia: Animal and Cell Models | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Neuroprotection of HP-beta-CD in the adult transgenic mice of Alzheimer disease |
Disclosure: Dr. Yao has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Systematic Review Investigating Relationship Between Neuromyelitis Optica Spectrum Disorder (NMOSD) and Vaccination |
Disclosure: Dr. Vanood has nothing to disclose.
|
Antithrombotic Treatment in Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Timing of Anti-Coagulation after Acute Ischemic Stroke and its relationship to risk of Intracranial Hemorrhage |
Disclosure: Dr. Shehzad has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. |
Disclosure: Dr. Thakore has received research support from Novartis Pharmaceuticals Corporation.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Cross-sensitivity of Psychiatric and Behavioral Side Effects with Antiepileptic Drug Use |
Disclosure: Dr. Chen has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | MRI changes in patients with newly diagnosed glioblastoma treated as part of a Phase II trial with bavituximab, radiation, and temozolomide |
Disclosure: Dr. Ly has nothing to disclose.
|
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Improving Patient Experience, Clinical Practice, and Provider Knowledge and Competence of Chronic Inflammatory Demyelinating Polyneuropathy with Online Continuing Medical Education |
Disclosure: Dr. Roc has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Comparative Profiling of Peripheral Blood Mononuclear Cells Proteome in Patients With Friedreich's Ataxia |
Disclosure: Dr. Pathak has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | The Effects of Alcohol Consumption on Cognitive Performance Using the King-Devick Rapid Number Naming Test and the Mobile Universal Lexicon Evaluation System |
Disclosure: Dr. Tejani has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Impact of Fremanezumab on Response Rates, Migraine Days, and Acute Medication Use in Patients with Chronic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication |
Disclosure: Dr. Silberstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Stephen D. Silberstein, MD, is a consultant and/or advisory panel member for and has received honoraria from Alder Biopharmaceuticals, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Labrys Biologics, Medscape, Medtronic, Neuralieve, NINDS, Pfizer, and Teva.. Dr. Silberstein has received research support from His employer receives research support from Allergan, Amgen, Cumberland Pharmaceuticals, ElectroCore Medical, Labrys Biologics, Eli Lilly, Merz, and Troy Healthcare..
|
Aging and Dementia: Animal and Cell Models | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer’s prone mice |
Disclosure: Dr. Cheung has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Neuromyelitis Optica Spectrum Disorders- Comparison as per Serostatus and Application of International Consensus Criteria |
Disclosure: Dr. Bali has nothing to disclose.
|
Antithrombotic Treatment in Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Treatment of floating thrombus with apixaban: report of a case. |
Disclosure: Dr. Soto-Rincon has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | The anatomical substrate of bulbar impairment in ALS: insights from multiparametric brainstem imaging, corticobulbar connectivity and somatotopic motor cortex measures |
Disclosure: Dr. Bede has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Psychiatric Effects of Ketogenic Diet Therapies on Adults with Chronic Epilepsy |
Disclosure: Dr. Shegelman has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | EEG Findings in Chimeric Antigen Receptor T-Cell (CAR-T) Related Encephalopathy Syndrome |
Disclosure: Dr. Satyanarayan has nothing to disclose.
|
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Severe Cerebellar Syndrome Improved with Plasma Exchanges in Patient with Lung Adenocarcinoma Treated with Durvalumab |
Disclosure: Dr. Tang has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Overwhelming genetic heterogeneity and exhausting molecular diagnostic process in chronic and progressive ataxias: Facing up with an algorithm, a gene, a panel at the same time. |
Disclosure: Dr. Zavala has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Investigating the Structure and Function of the Retinohypothalamic Tract in Neuromyelitis Optica by Optical Coherence Tomography (OCT) and Pupillometry |
Disclosure: Dr. Meltzer has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients With Episodic Migraine: Results of a 1-Year Study |
Disclosure: Dr. Brandes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Eli Lilly and Company, Depomed, Avanir Pharmaceuticals, Promius Pharma, and Supernus Pharmaceuticals. Dr. Brandes has received research support from Amgen, Eli Lilly and Company, CoLucid Pharmaceuticals, Teva Pharmaceuticals, Zosano, Allergan, and Biohaven Pharma.
|
Aging and Dementia: Animal and Cell Models | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Procognitive and neuroprotective effect of 5-HT7 agonist in an animal model by ICV amyloid-b injection |
Disclosure: Dr. Quintero Villegas has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | The Efficacy and Tolerability of Azathioprine for Patients with Neuromyelitis Optica Spectrum Disorder: A Systematic Review |
Disclosure: Dr. Espiritu has nothing to disclose.
|
Antithrombotic Treatment in Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Newer Anticoagulants in Patients with Atrial Fibrillation and Ischemic Stroke - a Two Year Experience |
Disclosure: Dr. Bhattacharya has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Neurophysiological Correlates of Excitability in ALS: Pretreatment Findings from the Retigabine and Mexiletine-2 Studies |
Disclosure: Dr. Weiss has received research support from ALS Association and ALS Finding a Cure.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Anxiety in Patients Admitted for Epilepsy Monitoring |
Disclosure: Dr. Panda has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Gliomatosis cerebri: Management and survival in the United States |
Disclosure: Dr. Garcia has nothing to disclose.
|
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Progressive Neurodegeneration in X-Linked Agammaglobulinaemia |
Disclosure: Dr. Gall has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Preclinical Assessment of TAK-831, a Selective D-Amino Acid Oxidase Inhibitor, in a Genetic Model of Friedreich’s Ataxia (YG8sR) |
Disclosure: Dr. Fradley has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Angio-OCT micro vascular markers and central auditory disorder as indipendent predictors of cognitive impairment in the Great Age Study population |
Disclosure: Dr. Sardone has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Chronic Migraine Patients Who Previously Used Topiramate |
Disclosure: Dr. Gandhi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals..
|
Aging and Dementia: Animal and Cell Models | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Structure and Pro-toxic Mechanism of the Human Hsp90/PPIase/Tau Complex |
Disclosure: Dr. Oroz has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Autonomic Dysfunction in People with Neuromyelitis Optica Spectrum Disorders |
Disclosure: Dr. Crnosija has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Serono.
|
Antithrombotic Treatment in Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Aspirin Resistance And Ischemic Stroke: A Prospective Study In Indian Population. |
Disclosure: Dr. Sisodia has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Neuroelectric Biomarkers of Network Dysfunction in Amyotrophic Lateral Sclerosis |
Disclosure: Dr. Nasseroleslami has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | A severe bone loss in pharmacoresistant epilepsy associates with enzyme-inducing antiepileptic drug |
Disclosure: Dr. Rigotti has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Incidence of Distant Recurrence in Adult Gliomas |
Disclosure: Dr. Pan has nothing to disclose.
|
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Safety of Checkpoint Inhibitors for Cancer Treatment in Patients with Multiple Sclerosis: A Case Report |
Disclosure: Dr. Isitan has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Ultrastructural Changes in Brain Stem Pathways in a Patient with Ataxia Associated with SPG7 Mutations |
Disclosure: Dr. Ringman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with InnoSense, LLC, RENEW. Dr. Ringman has received research support from Avid Pharmaceuticals.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Non-chiasmal bitemporal pseudo-hemianopia: case series |
Disclosure: Dr. Bingeliene has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Randomized, Double-Blind, Pilot Study Comparing 3 Mg Subcutaneous Sumatriptan With 6 Mg Subcutaneous Sumatriptan Using DFN-11 Autoinjector for the Acute Treatment Of Rapidly-Escalating Migraine Attacks |
Disclosure: Dr. Cady has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Full time employee at Alder BioPharmaceuticals, Inc..
|
Aging and Dementia: Animal and Cell Models | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Reciprocal regulation of filamin A and amyloid precursor protein expression in astrocytes |
Disclosure: Dr. Ekuta has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | The Effect of Pain on Quality of Life and Co-occurring Symptoms in Patients with Neuromyelitis Optica Spectrum Disorder |
Disclosure: Dr. Mealy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Viela Bio.
|
Antithrombotic Treatment in Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Smoking and Clopidogrel resistance in ischemic stroke |
Disclosure: Dr. Kang has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Do Sleep Scales Correlate with Pulmonary Function in ALS? Results From the ALS Nutrition/NIPPV Study Group |
Disclosure: Dr. Khazaal has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Anxiety and Depression Symptoms in the Epilepsy Clinic: Examining Psychiatric Treatment Characteristics in a Learning Health System Model |
Disclosure: Dr. Jones has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | CAR-T-cell-Related Encephalopathy Syndrome: High Rates of Neurotoxicity in Clinical Practice |
Disclosure: Dr. Yuen has nothing to disclose.
|
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Progressive Parkinsonism and Cognitive Changes: A Rare Presentation of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS) |
Disclosure: Dr. Khayatkhoei has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Updates to the National Institute of Neurological Disorders and Stroke (NINDS) Friedreich’s Ataxia (FA) Common Data Element (CDE) Recommendations: 2018 FA Working Group Review |
Disclosure: Dr. Gay has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Prognostic Factors of Poor Outcome in Idiopathic Intracranial Hypertension |
Disclosure: Dr. Farhat has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Long-Term Efficacy of Fremanezumab in Patients With Chronic Migraine With Concomitant Preventive Medication Use |
Disclosure: Dr. Yeung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals.
|
Aging and Dementia: Animal and Cell Models | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Impaired Brain Cells Response in Obesity |
Disclosure: Dr. Latif has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Development of Resistance to B-Cell Depletion Following Ten Years of Effective Rituximab Treatment in a Patient with Neuromyelitis Optica |
Disclosure: Dr. Harel has nothing to disclose.
|
Antithrombotic Treatment in Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | The Effect of New P2Y12 Receptor Antagonist, Ticagrelor, On Platelet Reactivity in Patients With Clopidogrel Resistance Undergoing Neuroendovascular Procedures. |
Disclosure: Dr. Jahngir has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Validation of the revised classification of cognitive and behavioral impairment in ALS |
Disclosure: Dr. Vasta has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | A survey of neurologists screening and management of depression in patients with epilepsy |
Disclosure: Dr. Riotto has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | A case series of metastatic glioblastoma at Memorial Sloan Kettering Cancer Center |
Disclosure: Dr. Noch has nothing to disclose.
|
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | The potential of Teriflunomide for regional and global brain volume protection in single subject MS patients |
Disclosure: Dr. Raji has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Serono, Genzyme, Novartis. Dr. Raji has received research support from Genzyme.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Frataxin deficiency causes excessive mitochondrial fragmentation associated with mitochondrial fission core components |
Disclosure: Dr. Johnson has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | The standard swinging flashlight test: reliable or not |
Disclosure: Dr. Boucher has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Safety Findings from the Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan for Acute Treatment of Migraine |
Disclosure: Dr. Krege has received compensation for employment at Eli Lilly and Company Dr. Krege holds stock and/or stock options in Eli Lilly.
|
Aging and Dementia: Animal and Cell Models | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Novel Insights into Intersectin1 Mechanistic Contributions to Brain Disorders |
Jessica Wilson Disclosure: Dr. Wilson has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | A Case of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy(GFAP) Meningoencephalomyelitis Responsive to Infliximab |
Disclosure: Dr. Rodriguez has nothing to disclose.
|
Antithrombotic Treatment in Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Retrospective Comparison of Medication Therapy Management and Stroke/TIA Outcomes in Patients Who Have Undergone Testing for Antiplatelet Responsiveness and Pharmacist Intervention and versus Those Who Have Not |
Disclosure: Dr. Westphal has received research support from ASHP, Acadia, Dent Family Foundation.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Genetic Testing Has a High Diagnostic Yield for Individuals with ALS regardless of Family History |
Disclosure: Dr. Yang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GeneDx.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Symptoms and Impacts in Epilepsy: Findings from Qualitative Patient Interviews |
Disclosure: Dr French did not receive personal income, but received NYU salary support from the Epilepsy Foundation and for consulting work and/or attending Scientific Advisory Boards on behalf of the Epilepsy Study Consortium for Acadia, Adamas, Addex, Aeonian, Alexza, Anavex, Axcella Health, Axovant, Biogen, Biomotiv/Koutif, Blackfynn, Bloom Science, Bridge Valley Ventures, Cavion, Cerebral Therapeutics, Cerevel, Clinilabs, Concert Pharmaceuticals, Covance, Crossject, CuroNZ, Eisai, Empatica, Engage Therapeutics, Epitel, GW Pharma, Idorsia, Impax, Ionis, J&J Pharmaceuticals, Marinus, MonosolRx, Neurelis, Novartis, Otsuka Pharmaceutical Development, Ovid Therapeutics Inc., Pfizer, Pfizer-Neusentis, Praxis, Redpin, Sage, Sancillio, Shire, SK Life Sciences, Springworks, Stoke, Sunovion, Supernus, Takeda, UCB Inc., Ultragenyx, Upsher Smith, Vyera, West Therapeutic Development, Xenon, Xeris, Zogenix, Zynerba. Dr. French has received research support from Biogen, Cavion, Eisai, Engage, GW Pharma, Lundbeck, Neurelis, Ovid, SK Life Sciences, Sunovion, UCB, and Zogenix as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, and NINDS. .
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Primary brain tumors admitted to the neurological intensive care unit: a single institution observational study |
Disclosure: Dr. Kang has nothing to disclose.
|
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Acute disseminated encephalomyelitis following Mycoplasma pneumoniae infection in a young adult collegiate athlete |
Disclosure: Dr. Kyrtsos has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Structural Magnetic Resonance Imaging Correlates of Neurodegeneration in a Spinocerebellar Ataxia Type 7 Cohort |
Disclosure: Dr. Parker has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Acute Optic Neuritis: looking for an accurate and early assessment |
Disclosure: Dr. Fernandez has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Evaluation of Cardiovascular Risks in Adult Patients with Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies |
Disclosure: Employment: Eli Lilly and Company Employee and minor stockholder of Eli Lilly and Company
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Age of onset in genetic prion disease and the design of preventive clinical trials |
Disclosure: Dr. Minikel has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Neuromyelitis Optica Spectrum Disorder in a Tertiary Hospital in the Philippines: A Case Series |
Disclosure: Dr. Espiritu has nothing to disclose.
|
Antithrombotic Treatment in Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Fourteen-day Delay of Cerebral Ischemia due to Vasospasm after Traumatic Subarachnoid Hemorrhage in Mild Head Injury |
Disclosure: Dr. Maran has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | The Canadian ALS Neuroimaging Consortium (CALSNIC) |
Disclosure: Dr. Kalra has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Impact of Autism Spectrum Disorder Diagnosis on Epilepsy in Patients with Tuberous Sclerosis Complex |
Disclosure: Dr. Drogin has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Patterns of Death and Palliative Care in Glioma Patients |
Disclosure: Dr. Barbaro has nothing to disclose.
|
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Acute and Lasting Benefits of a Virtual Reality in Multiple Sclerosis |
Disclosure: Dr. Shaw has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Inpatient Verses Outpatient Workup of Patients with Ataxia and Suspected Paraneoplastic Cerebellar Degeneration: Does Workup Location Matter? |
Disclosure: Dr. Witek has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Transcriptional control of optic nerve injury associated retinal ganglion cell death |
Disclosure: Dr. Syc has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Efficacy of Fremanezumab in Migraine Patients Who Have Failed at Least One Prior Migraine Preventive Medication |
Disclosure: Dr. McAllister has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen Inc., Teva Neuroscience, Alder, Promius, Electrocore, and Allergen, Inc. Dr. McAllister has received personal compensation in an editorial capacity for Practical Neurology. Dr. McAllister has received research support from Alder, Amgen Inc., Teva Neuroscience, Sunovion, San-bio, Biohaven, Allergan, Inc., Novartis, ATI, Roche Diagnostics Corporation, Esai Inc., and Biogen Idec.
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Tau and neurodegeneration mismatch is a signature of polypathology in AD continuum |
Disclosure: Dr. Wolk has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Neuronix. Dr. Wolk has received research support from Avid/Lilly, Biogen, and Merck.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Area Postrema syndrome: A Short Case Series Highlighting Diagnostic dilemmas, Clinical features and Outcome |
Disclosure: Dr. Nadig has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | The Role of Intravenous Thrombolysis in the Prediction of Functional Outcome in Patients who undergo Endovascular Thrombolysis with Newer Generation Stent Retrievers |
Disclosure: Dr. aijb has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Relationship between Forced Vital Capacity and Slow Vital Capacity in individuals with Amyotrophic Lateral Sclerosis Patients |
Disclosure: Dr. Reynolds has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Employment and socioeconomic status after epilepsy surgery: A study in a Mexican cohort. |
Disclosure: Dr. Jorge De Sarachaga has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Psychiatric Disturbance As a Presenting Symptom in Central Nervous System Lymphoma |
Disclosure: Dr. Sharma has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Cerebellar endoplasmic reticulum-mitochondria calcium signal pathways are impaired in the KIKO mouse model of Friedreich ataxia |
Disclosure: Dr. Lin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Impel NeuroPharma. Dr. Lin has received research support from Impel NeuroPharma.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Dwarf gecko as a model for studying retinal neurogenesis |
Disclosure: Dr. Mendez has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Chronic Migraine Patients With Concomitant Preventive Medication Use |
Disclosure: Dr. Gandhi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals..
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Interactions Between Brain Structures and Genetic Variants in Neurotransmitter Systems as Potential Biomarkers for Hallucinations and Delusions in Alzheimer’s Disease |
Disclosure: Dr. Ahmed has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | An Atypical NMO Presentation with Locked-In Syndrome |
Disclosure: Dr. Rehman has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Does Use of Adjunctive Therapy to Mechanical Thrombectomy Improve Outcomes Without Significant Risk in LVOs. |
Disclosure: Dr. Singh has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | MRI Alterations in the Brachial Plexus of ALS Patients |
Disclosure: Dr. Scamarcia has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Quality Of Life And Disease Progress In Patients With Drug Resistant Epilepsy |
Disclosure: Dr. Olivas has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Characterization of Seizures (ILAE 1981 and 2017 Classifications) and their Response to Treatment in a Cohort of Patients with Glial Tumors. |
Disclosure: Dr. Casas-Parera has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Ataxia with Transglutaminase 6 Mutation (SCA35) Responding to Gluten-Free Diet: A Case Report |
Disclosure: Dr. Lin has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Inferior colliculus neurons that express the neuropeptide VIP project to auditory nuclei in the brainstem and thalamus. |
Disclosure: Mr. Edelbrock has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Improvement in Response Over Time With Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification |
Disclosure: Dr. Halker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Biohaven, and Allergan. Dr. Halker has received personal compensation in an editorial capacity for Current Neurology & Neuroscience Reports.
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Longitudinal Decline in Lexical Retrieval is Related to AD Pathologic Burden in Middle Frontal, Superior and Temporal Regions in Progressive Aphasia |
Disclosure: Dr. Bove has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Clinical characteristics, diagnostic and outcome differences in patients with optic neuritis |
Disclosure: Dr. Siegel has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Prior Intravenous Thrombolytics Administration is Associated with Increased Hospital Bills & Intracranial Hemorrhage Rates Without Improved Outcomes in Mechanical Thrombectomy Patients |
Disclosure: Dr. Hassan has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Intrathecal delivery of ALS cerebrospinal fluid induces motor deficits and motor neuron death in mice |
Disclosure: Dr. Wong has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Factors Associated with Quality of Life in a Low-income Population with Epilepsy. |
Disclosure: Dr. Espinosa Jovel has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Prognostic Factors and Survival in Primary CNS Lymphoma Patients at Yale |
Disclosure: Dr. Prado has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Diagnostic Value of Next Generation Sequencing Ataxia Panel as a Part of Multistep Investigation Approach in Sporadic and Autosomal Recessive Cerebellar Ataxias in Russia |
Disclosure: Dr. Seliverstov has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Delayed Development of a Dural AV Fistula and PTEN Hamartoma Syndrome in Pseudo-Idiopathic Intracranial Hypertension |
Disclosure: Dr. Gold has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Single and Multiple Doses of Ubrogepant Are Not Associated With a Clinically Significant Elevation of Alanine Aminotransferase in Healthy Adult Males |
Disclosure: Dr. Bondiskey has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Sharp & Dohme Corp. Dr. Bondiskey holds stock and/or stock options in Merck Sharp & Dohme Corp., which sponsored research in which Dr. Bondiskey was involved as an investigator.
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Hippocampal tau pathology burden in Lewy body disorders |
Disclosure: Dr. Ittyerah has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Spectral-Domain Optical Coherence Tomography in Autoimmune Disorders with Optic Neuropathy: A Retrospective Analysis of Distinctive Features. |
Disclosure: Dr. Sriwastava has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Outcome of mechanical thrombectomy in patients with acute ischemic stroke on anticoagulation therapy |
Disclosure: Dr. Karim has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Radicava® (edaravone) for Amyotrophic Lateral Sclerosis: New Formulation and Its Development Plan |
Disclosure: Dr. Takei has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Mitsubishi Tanabe Pharma Corporation, Inc.. Dr. Takei holds stock and/or stock options in Mitsubishi Tanabe Pharma Corporation, Inc. which sponsored research in which Dr. Takei was involved as an investigator. .
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Effect of Seizure Auras on Mood in Epilepsy: the ESAME Survey |
Disclosure: Dr. Bumsch has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Feasibility of a Structured Tumor-related Epilepsy Education Intervention in Adult Gliomas |
Disclosure: Dr. Wasilewski has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Autosomal Recessive Spastic Ataxia of Charlovoix-Saguenay. A new pathogenic mutation. |
Disclosure: Dr. Flanigan has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Vancomycin Ototoxicity May Lead to Bilateral Vestibular Hypofunction |
Disclosure: Dr. Zak has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Long-Term Safety of Fremanezumab: Results of a 1-Year Study |
Disclosure: Dr. Ning has nothing to disclose.
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Neuropathological findings in Parkinson’s disease with mild cognitive impairment |
Disclosure: Dr. Knox has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Utilizing T-Cell Suppression In Recurrent GFAP Antibody Encephalitis |
Disclosure: Dr. Nicholson has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Monitored anesthesia care by sedation-trained providers in acute stroke thrombectomy. |
Disclosure: Dr. Slawski has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | BRIDGE: Dynamic Imagery and Art Therapy in ALS- A Clinical Study to Improve Patient Expression and Wellness |
Disclosure: Dr. King has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Self-Reported Depression and Anxiety Scores Similar in Patients with Temporal and Extra-Temporal Lobe Epilepsy |
Disclosure: Dr. Abe has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Primary CNS posttransplant lymphoproliferative disease (PCNS-PTLD): Diagnosis, minimal treatment toxicity, and surveillance in renal transplant patients |
Disclosure: Dr. Summers has nothing to disclose.
|
Ataxia | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Opsoclonus Myoclonus Ataxia Related to West Nile Virus |
Disclosure: Dr. Boucekkine has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Observation of Angular Deformity of a Straight Line |
Disclosure: Dr. Tishman has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Assessment of the Long-Term Safety and Efficacy of Erenumab During Open-Label Treatment of Patients With Chronic Migraine |
Disclosure: Dr. Tepper has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Alder, Alexsa, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, BioDelivery Sciences International, Biohaven, Charleston Labs, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano. Dr. Tepper has received personal compensation in an editorial capacity for American Headache Society. Dr. Tepper has received research support from Alder, Allergan, Amgen, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Teva, and Zosano.
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | RS4548513 (CTNNA3): A Genetic Risk Factor for Visual Construction Deficiency in Parkinson's disease |
Disclosure: Dr. Murezzan has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | A Case of an Aggressive Demyelinating NMO Spectrum Disorder-like Event in a Rheumatoid Arthritis Patient Treated with Tofacitinib |
Disclosure: Dr. Eckert has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | General Anesthesia for Thrombectomy in Ischemic Stroke Leads to Poor Outcomes as Compared to Conscious Sedation |
Disclosure: Dr. Bhan has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Predicting benign brachial monomelic amyotrophy: factors at presentation that differentiate from amyotrophic lateral sclerosis |
Disclosure: Dr. Mistry has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Seizure-induced demargination predicts peri-ictal respiratory decompensation |
Disclosure: Dr. Vega has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Telehealth for Specialty Neurofibromatosis (NF) Care |
Disclosure: Dr. Jordan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Recursion Pharmaceuticals, NF Network, and Elsevier Publishing.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Results of an Open Label, Dose Escalating, Phase 1 Clinical Trial Evaluating the Safety of a Human Neural Stem Cell Based Therapy in Parkinson’s Disease |
Disclosure: Dr. Kern has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with International Stem Cell Corporation. Dr. Kern has received compensation for serving on the Board of Directors of International Stem Cell Corporation. Dr. Kern holds stock and/or stock options in International Stem Cell Corporation which sponsored research in which Dr. Kern was involved as an investigator. . Dr. Kern holds stock and/or stock options in International Stem Cell Corporation. Dr. Kern has received research support from International Stem Cell Corporation.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Herpes Simplex Virus (HSV)-2 Meningoencephalitis-associated Bilateral Optic Neuritis Successfully Treated with Steroids and Intravenous Immunoglobulin |
Disclosure: Dr. El Ammar has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Immunogenicity Assessment from Phase 3 Galcanezumab Trials in Patients with Episodic or Chronic Migraine |
Disclosure: I am full-time employee and a stock shareholder of Eli Lilly and Company.
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Genetic Polymorphisms Associate with Frontotemporal Cortical Thickness in Sporadic Amyotrophic Lateral Sclerosis |
Disclosure: Dr. Placek has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Anti-APQ4-negative NMO Spectrum Disorders with and without anti-MOG: A Retrospective Case Series |
Disclosure: Dr. Mirzoev has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | The first objective predictor of the hemorrhagic events after endovascular treatment of acute ischemic stroke using 2D parametric parenchymal blood flow |
Disclosure: Dr. Elsaid has nothing to disclose.
|
Epilepsy: Comorbidities and SUDEP | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Quantitative Pupil Measurements In Epileptic Seizures And Non-Epileptic Events – A Step Towards SUDEP Pathophysiologic Mechanisms. |
Disclosure: Dr. Yerram has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Pineal parenchymal tumors of intermediate differentiation treated with ventricular radiation and temozolomide |
Disclosure: Dr. Low has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | PD-1102: A Phase 1 study of VY-AADC01 Administered Using a Posterior Approach in Patients with Parkinson’s Disease and Motor Fluctuations |
Disclosure: Dr. Van Laar has received research support from Biogen.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | A Chronic Progressive Optic Neuropathy in a Patient with Anti-Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies |
Disclosure: Dr. Gold has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Absence of Clinically Significant Drug Interactions With Coadministration of Ubrogepant and an Ethinyl Estradiol/Norgestimate Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis |
Disclosure: Dr. Li has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co, Inc.
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Exome sequencing in carriers of the C9orf72 repeat mutation to identify pathogenic variants in other neurodegenerative genes |
Disclosure: Dr. Tran has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Paraneoplastic Neuromyelitis Optica Spectrum Disorder in a Patient with Endometrial Adenocarcinoma |
Disclosure: Dr. Granger has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | The Processing Time for Recanalization and Size of Ischemic Lesions on DWI Is Related with Complete Reperfusion After Mechanical Thrombectomy |
Disclosure: Dr. Shin has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | An Update of Study of ALS Reversals: LifeTime Exposures (StARLiTE) |
Disclosure: Dr. Crayle has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Utilizing Optical Coherence Tomography to Assess the Effect of Phenytoin on Retinal Structures in Epilepsy Patients |
Disclosure: Dr. Gilroy has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | A Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma |
Disclosure: Dr. Rogers has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | “Dual Frequency” Deep Brain Stimulation Programming Paradigm for Gait and Balance Impairment in Parkinson’s Disease |
Disclosure: Dr. Karl has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Saturday Night Retinopathy – A Rare Case of Acute Onset Vision Loss and Ophthalmoplegia |
Disclosure: Dr. Dorotan has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Absence of Clinically Significant Drug Interactions With Coadministration of Atogepant and an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis |
Disclosure: Dr. Ankrom has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co, Inc.. Dr. Ankrom holds stock and/or stock options in Merck & Co, Inc., which sponsored research in which Dr. Ankrom was involved as an investigator.
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | TDP-43 cytoplasmic inclusion formation in C9orf72-associated FTLD/ALS |
Disclosure: Dr. Lee has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | The Essence and Boundaries of anti-Myelin Oligodendrocyte Glycoprotein Syndromes |
Disclosure: Dr. Liu has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Inter-facility transfer workflow for thrombectomy in a rural stroke network: Longer Door-In-Door-Out (DIDO) time delays thrombectomy |
Disclosure: Dr. Abdelhak has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Health utility declines with advancing Fine'til 9 stage of ALS |
Disclosure: Dr. Thakore has received research support from Novartis Pharmaceuticals Corporation.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Safety of Cenobamate (YKP3089) as Adjunctive Treatment for Uncontrolled Focal Seizures in a Large, Multicenter, Open-Label Study |
Disclosure: Yes: all funds paid to Thomas Jefferson University with research support from Medtronic, SK Life Science, Takeda, UCB Pharma, Neurelis, Eisai, Engage, Cavion
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Impact of Delay of Chemoradiation (CRT) in Newly Diagnosed Glioblastoma (GBM) Treated With Stupp Protocol |
Disclosure: Dr. Ali has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | National Trends in Utilization of Deep Brain Stimulation In Primary Movement Disorders: National Inpatient Sample Study 2006-2014 |
Disclosure: Dr. Vellipuram has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | A Case of Heidenhain Variant Creutzfeldt-Jakob Disease Presenting with Isolated Homonymous Quadrantanopia and Corresponding Nuclear Imaging Findings |
Disclosure: Dr. Bhadola has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Long-term Efficacy of Erenumab in Patients With Episodic Migraine Who Have Failed Prior Preventive Migraine Therapies |
Disclosure: Dr. Reuter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting fee, speaking/teaching fee, from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, EliLilly, Medscape, Novartis, StreamMedUp, TEVA Pharmaceuticals. Dr. Reuter has received research support from research grants from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, EliLilly, Medscape, Novartis, StreamMedUp, TEVA Pharmaceuticals.
|
Aging and Dementia: Genetics and Neuropathology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Small Vessel Characteristics of Autopsied Patients with CADASIL and Those Heterozygous for HTRA1 Mutations: 3D Analysis Using the CUBIC Tissue Clearing Technique |
Disclosure: Dr. Saito has nothing to disclose.
|
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) into Subjects with Transverse Myelitis (TM) |
Disclosure: Ms. Cameron Watts has received research support from Myeletis Organization.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | RAPIDTM Based Treatment Algorithms Lead to Faster Activation of Neurointervention Team and Reduce Recanalization Times |
Disclosure: Dr. Mehta has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients |
Disclosure: Dr. Johannesen has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Analysis of Psychiatric Adverse Events and Suicidality in Clinical Trials of Adjunctive Eslicarbazepine Acetate in Children (Aged 4–17 Years) with Focal Seizures |
Disclosure: Dr. Salpekar has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion Pharmaceuticals Inc. (consulting only). Dr. Salpekar has received research support from Lundbeck (institution only).
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Neurological Adverse Effects Due to Programmed Death (PD-1) Inhibitors |
Disclosure: Dr. Shi has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Correlation of Electrode Location and Outcomes of Gait and Axial Function in Parkinson’s Disease Patients managed with Subthalamic Deep Brain Stimulation |
Disclosure: Dr. Huang has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Posterior Ischemic Optic Neuropathy, a previously unknown complication of lung transplantation |
Disclosure: Dr. Keller has nothing to disclose.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | The Use of Standing Desks to Address Self-Regulating Behavior in Elementary Students |
Disclosure: Dr. Wachob has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine Over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR) |
Disclosure: Dr. Brandes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Eli Lilly and Company, Depomed, Avanir Pharmaceuticals, Promius Pharma, and Supernus Pharmaceuticals. Dr. Brandes has received research support from Amgen, Eli Lilly and Company, CoLucid Pharmaceuticals, Teva Pharmaceuticals, Zosano, Allergan, and Biohaven Pharma.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | The Structural Basis of Susac's Syndrome |
Disclosure: Dr. Munoz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cortexyme.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | To Stay or To Go? Utilization of a Mobile Interventional Stroke Team Shortens Time to Treatment in Large Vessel Occlusion |
Disclosure: Dr. Velickovic Ostojic has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Increasing the Efficiency of ALS Clinical Trials Using Machine Learning |
Disclosure: Dr. Ennist has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Origent Data Sciences.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Safety and Efficacy of Adjunctive Perampanel in Younger (aged 4 to <7 years) and Older (7 to <12 years) Pediatric Patients with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Final Results from the 311 Core Study |
Disclosure: Dr. Fogarasi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB and Novartis.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | The Financial Burden of Central Nervous System Cancers in the United States |
Disclosure: Dr. Pena has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | The Use of Omni vs. Directional Programming in Parkinson Disease and Essential Tremor DBS Patients |
Disclosure: Dr. Sharma has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Wernicke Encephalopathy Mimicking Idiopathic Intracranial Hypertension |
Disclosure: Dr. Leon has nothing to disclose.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Model-Based Truncation of Cognitive Test Batteries to Minimize Assessment Time and Information Loss |
Disclosure: Dr. Vermeent has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Philips.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Long-Term Impact of Fremanezumab on Headache-Related Disability and Quality of Life in Patients Who Reverted From a Chronic to an Episodic Migraine Classification |
Disclosure: Dr. Ailani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Amgen, Allergan. Eli Lilly and Company,Teva, Impel, Satsuma, Miller Communications, Avent, Revance, Biohaven, Zosano. Dr. Ailani has received personal compensation in an editorial capacity for Current Pain and Headache Reports Section Editor. Dr. Ailani has received research support from American Migraine Foundation, Biohaven, Allergan, Eli Lilly and Co, Zosano.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Progressive Brain Atrophy and Leptomeningeal Enhancement in Susac Syndrome |
Disclosure: Dr. Malik has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Initial symptoms and delay in treatment of patients with posterior circulation strokes undergoing endovascular therapy |
Disclosure: Dr. Gomez has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | How the National Amyotrophic Lateral Sclerosis (ALS) Registry Can Help with Your Research |
Disclosure: Dr. Kaye has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with McKing Consulting Corp.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Analysis of Allergic Reactions in Clinical Trials of Eslicarbazepine Acetate in Children (Aged 4–17 Years) with Focal Seizures |
Disclosure: Dr. Resnick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Sunovion Pharmaceuticals Inc., Supernus, Mallinckrodt.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Facial palsy induced by cancer immunotherapy: a single center retrospective study |
Disclosure: Dr. Yuen has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | APOE E4 Carrier Status Modulates Cognitive Outcome after Deep Brain Stimulation in Parkinson’s Disease Patients |
Disclosure: Dr. Yoon has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Acute Bilateral Ophthalmoparesis due to Bacterial Meningitis in the Setting of Sphenoid Sinusitis |
Disclosure: Dr. Pereira has nothing to disclose.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Impact of Educational Inequality on the Incidence of Post-stroke Vascular Mild Cognitive Impairment - Application of the Previous Study on Stratified Education-adjusted MoCA Assessment |
Disclosure: Dr. Pisanuwongrak has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Eptinezumab Reduces Migraine Frequency Within the First Month After Treatment in Patients with Episodic or Chronic Migraine |
Disclosure: Dr. Winner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Supernus, Teva, Novartis, Avanir, and Promius.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Pachymeningitis in Rheumatic Disease |
Disclosure: Dr. Kneeland has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Posterior Circulation Large Vessel Occlusions are Associated with Longer Door-?to-Groin Time |
Disclosure: Dr. Almallouhi has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Characteristics of respiratory dysfunction in amyotrophic lateral sclerosis: a retrospective cohort study in 236 cases |
Disclosure: Dr. Fu has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | A Two-Part, Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Patients with Epilepsy with a Predictable Seizure Pattern: Results from the Initial Open-Label Feasibility Part |
Disclosure: Dr French did not receive personal income, but received NYU salary support from the Epilepsy Foundation and for consulting work and/or attending Scientific Advisory Boards on behalf of the Epilepsy Study Consortium for Acadia, Adamas, Addex, Aeonian, Alexza, Anavex, Axcella Health, Axovant, Biogen, Biomotiv/Koutif, Blackfynn, Bloom Science, Bridge Valley Ventures, Cavion, Cerebral Therapeutics, Cerevel, Clinilabs, Concert Pharmaceuticals, Covance, Crossject, CuroNZ, Eisai, Empatica, Engage Therapeutics, Epitel, GW Pharma, Idorsia, Impax, Ionis, J&J Pharmaceuticals, Marinus, MonosolRx, Neurelis, Novartis, Otsuka Pharmaceutical Development, Ovid Therapeutics Inc., Pfizer, Pfizer-Neusentis, Praxis, Redpin, Sage, Sancillio, Shire, SK Life Sciences, Springworks, Stoke, Sunovion, Supernus, Takeda, UCB Inc., Ultragenyx, Upsher Smith, Vyera, West Therapeutic Development, Xenon, Xeris, Zogenix, Zynerba. Dr. French has received research support from Biogen, Cavion, Eisai, Engage, GW Pharma, Lundbeck, Neurelis, Ovid, SK Life Sciences, Sunovion, UCB, and Zogenix as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, and NINDS. .
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Planning a Glioma Partial Resection with DTI Tractography and Virtual Reality |
Disclosure: Dr. Sanicola has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Using a quality improvement framework to examine deep brain stimulation in Parkinson’s disease: the RAD-PD initiative |
Disclosure: Dr. Jimenez Shahed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with St. Jude Medical/Abbott, Medtronic, Boston Scientific, Teva, Bracket,Nuvelution, Sunovion,. Dr. Jimenez Shahed has received research support from Medtronic, St. Jude Medical/Abbott, Lily, Wilsons Therapeutics, Sunovion, Nuvelution.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Optic Neuritis and Intracranial Hypertension Caused by Chronic Lymphocytic Leukemia, Case Report |
Disclosure: Dr. Madani has nothing to disclose.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Using the Montreal Cognitive Assessment (MoCA): to Predict Three Month Recovery Following a Stroke |
Disclosure: Dr. Julayanont has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Long-Term Efficacy of Fremanezumab in Patients With Chronic Migraine and Comorbid Moderate to Severe Depression |
Disclosure: Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. Dr. Lipton has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Lipton holds stock and/or stock options in Biohaven, which sponsored research in which Dr. Lipton was involved as an investigator. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Lipton has received research support from Migraine Research Foundation, the National Headache Foundation, and Amgen.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Clinical spectrum of patients with Primary central nervous system vasculitis |
Disclosure: Dr. Dash has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | First Pass Rates Differ Between Anterior Circulation And Vertebrobasilar Occlusions During Mechanical Thrombectomy For Emergent Large Vessel Occlusions |
Disclosure: Dr. Daniel has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | McGill University Single Item Quality-of-Life ( QoL ) Scale Compared with ALS Health-Related Quality-of-Life Likert Scales Including Breathing QoL Measurement |
Disclosure: Dr. Brooks has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Mitsubishi Tanabe Pharma USA, Biohaven, Cytokinetics, ITF Pharma. Dr. Brooks has received personal compensation in an editorial capacity for American Journal of Managed Care. Dr. Brooks has received research support from Medicinova, Neuraltus, Cytokinetics,Santhera, Biogen, ITF Pharma, Acceleron, Center for Disease Control, Orion, Biohaven.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | A Post-Marketing Observational Study to Evaluate the Safety and Tolerability of Perampanel as Add-On Therapy in Patients with Epilepsy Aged =12 Years |
Disclosure: Dr. Maguire has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | iPROMPT: Integrated Predictive Radiographic biOMarkers of Progressed high grade astrocytic Tumors |
Disclosure: Dr. Gatson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novocure (Optune).
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | CLOVER-DBS: A Prospective, Multicenter Clinical Study with Blinding to Evaluate a Closed Loop Programming Algorithm for Directional Leads Based on External Feedback |
Disclosure: Dr. Wenzel has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Binasal Visual Field Defects in a Child with Acute Necrotizing Encephalopathy |
Disclosure: Dr. Liu has nothing to disclose.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Concordance Between Structural and Functional Connectivity Reflects Available Cognitive Reserve in Multiple Sclerosis During Cognitive Rehabilitation |
Disclosure: Dr. Fuchs has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Early Impact of Eptinezumab on the Health-Related Quality of Life (HRQoL) of Patients with Episodic or Chronic Migraine: SF-36 Analysis Across the Spectrum of Migraine |
Disclosure: Dr. Diamond has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder BioPharmaceuticals, Amgen Inc., Avanir Pharmaceuticals, Depomed Inc., Eli Lilly and Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceuticals, and Upsher-Smith Laboratories.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Case of hypertrophic pachymeningitis with positive MPO-ANCA antibodies |
Disclosure: Dr. Castrodad- Molina has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | No Association Between Number of Stent Retriever Passes and Hemorrhagic Transformation for Mechanical Thrombectomy Patients. |
Disclosure: Dr. Hassan has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Safety and Efficacy of Edaravone in Delaying Functional Decline in Amyotrophic Lateral Sclerosis: A Meta-Analysis |
Disclosure: Dr. Bagnas has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Analysis of Hepatic and Hypothyroidism-related Events in Clinical Trials of Adjunctive Eslicarbazepine Acetate in Children (Aged 4–17 years) with Focal Seizures |
Disclosure: Dr. Wheless has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck, Mallinckrodt, LivaNova, Eisai, Supernus, GW Pharma, NeuroPace, UCB, Actua, and Aquestive. Dr. Wheless has received research support from NIH, Shainberg Foundation, Mallinckrodt, LivaNova, Eisai, GW Pharma, INSYS Inc, Neuralis, Zogenix, NeuroPace, UCB, Actua, and Aquestive.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | NeMeRe, a Multi-Institutional Retrospective and Prospective Registry of Neoplastic Meningitis in Adults |
Disclosure: Dr. Ghatnekar has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Monitoring Safety and Effectiveness of Deep Brain Stimulation Systems in a Real-World Population: The Product Surveillance Registry |
Disclosure: Dr. Pagan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion, Teva, Acadia, Adamas, AbbVie, Medtronic, US Word Meds, Merz.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Perceptions of Treatment, Care After Hospital Discharge, and Recovery Following Autoimmune and Infectious Encephalitis |
Disclosure: Dr. Nyamu has nothing to disclose.
|
Headache Clinical Trials I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | The Impact of Fremanezumab on Medication Overuse in Patients With Chronic Migraine |
Disclosure: Dr. Silberstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Stephen D. Silberstein, MD, is a consultant and/or advisory panel member for and has received honoraria from Alder Biopharmaceuticals, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Labrys Biologics, Medscape, Medtronic, Neuralieve, NINDS, Pfizer, and Teva.. Dr. Silberstein has received research support from His employer receives research support from Allergan, Amgen, Cumberland Pharmaceuticals, ElectroCore Medical, Labrys Biologics, Eli Lilly, Merz, and Troy Healthcare..
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Wet, Wacky, and Wobbly Without Hydrocephalus |
Disclosure: Dr. Hung has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Did Evolution of Evidence Based Stroke Thrombectomy Treatment Change Efficiency Across Stroke Systems of Care? |
Disclosure: Dr. Kulhari has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Pitfalls in the Diagnosis of Amyotrophic Lateral Sclerosis in a Hispanic Cohort |
Disclosure: Dr. Trikamji has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Selective T-type Calcium Channel Modulator CX-8998 Fully Suppresses Seizures in the GAERS Genetic Model of Epilepsy at Human Achievable Concentrations |
Disclosure: Dr. Lee has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cavion Inc., Karyopharm Therapeutics, and Evelo Biosciences.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Neurological Complications in an ALS Patient with Metastatic Melanoma after Immunotherapy |
Disclosure: Dr. Jaffer has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Two Year Outcomes: A Prospective, Double Blinded, Multicenter Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson's Disease (INTREPID) |
Disclosure: Dr. Vitek has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Boston Scientific, Abbott, Medtronic. Dr. Vitek has received research support from Boston Scientific, Abbott, Medtronic.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | A Common Data Language for Clinical Research Studies: Overview and Update on the National Institute of Neurological Disorders and Stroke (NINDS) Common Data Element (CDE) Recommendations |
Disclosure: Dr. Sheikh has nothing to disclose.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | The Contribution of Cognitive Impairment to Perceived Motor Disability in Amyotrophic Lateral Sclerosis |
Disclosure: Dr. Ahmadi Jazi has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Adult acute hemorrhagic leukoencephalitis: role of susceptibility-weighted imaging in diagnosis and importance of aggressive early immunotherapy. |
Disclosure: Dr. Sugar has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Evidence Improves Outcomes Beyond ‘Belief’: Comparison of Patient Outcomes in Pre- and Post- DAWN era. |
Disclosure: Dr. Kulhari has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Clinical and Electrophysiological Profile and Study of Plasma Levels of Neurotoxic Metals in Amyotrophic Lateral Sclerosis |
Disclosure: Dr. Garuda has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Cosyntropin is poorly effective in treatment of infantile spasms |
Disclosure: Dr. Arya has nothing to disclose.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Eye Movement Abnormalities in CNS Germ Cell Tumors |
Disclosure: Dr. Sarangi has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | The STN Sweet Spot for Tremor Control in Parkinson’s Disease. |
Disclosure: Dr. Stiep has nothing to disclose.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Evaluation of microRNAs in patients with sporadic amyotrophic lateral sclerosis by liquid biopsy as a disease biomarker |
Disclosure: Dr. Takahashi has nothing to disclose.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Identifying Neural Activity Related to Both How and Why Movements are Performed |
Disclosure: Dr. Mazurek has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Rheumatoid Meningitis with Elevated Cyclic Citrullinated Peptide Antibodies and No Evidence of Arthritic Disease |
Disclosure: Dr. Rose has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Impact of Race on Mechanical Thrombectomy Safety Outcomes |
Disclosure: Dr. Liaw has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Lifetime Sport Practice and Brain Metabolism in Amyotrophic Lateral Sclerosis: a 18F-FDG-PET study |
Disclosure: Dr. Moglia has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | A 12-month, open-label, repeat-dose safety study of Valtoco ™ (NRL-1, diazepam nasal spray) in patients with epilepsy: Interim report |
Disclosure: Yes: all funds paid to Thomas Jefferson University with research support from Medtronic, SK Life Science, Takeda, UCB Pharma, Neurelis, Eisai, Engage, Cavion
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Standardized Intrathecal (IT) Treatment and Surveillance in Leptomeningeal Carcinomatosis (LMC) Improves Patient Outcomes: developing Ommaya IT chemotherapy clinics |
Disclosure: Dr. Leese has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Characteristics of oscillatory activity in the globus pallidus internus in patients with Parkinson’s disease |
Disclosure: Dr. Zhuang has nothing to disclose.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Molecular background of ALS based on whole exome sequencing analysis |
Disclosure: Dr. Hama has nothing to disclose.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Polyphenolic compounds ameliorate stress–induced depression by preventing NLRP3 inflammasome priming |
Disclosure: Dr. Frolinger has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Progressive Multifocal Leukoencephalopathy in a Patient with Relapsed Multiple Myeloma: A Case Report and Literature Review |
Disclosure: Dr. Woodson has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Patterns and Outcomes of Endovascular Therapy in Mild Stroke: A Florida-Puerto Rico Collaboration |
Disclosure: Dr. Asdaghi has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Case Report: Familial Amyotrophic Lateral Sclerosis SOD1 c.122A>G (p.Glu41Gly) Mutation with Slow Disease Progression |
Disclosure: Dr. Nguyen has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Pharmacokinetic (PK) Assessment of Perampanel Intravenous (IV) Formulation as a Bioequivalent Alternative to Oral Tablet Administration |
Disclosure: LR is an employee of Eisai Inc.
|
Clinical Advances in CNS Cancer Care | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Treatment of Cerebral Cysts with Ommaya Reservoir – A Review of 4 Cases |
Disclosure: Dr. Mayers has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Longitudinal outcomes of LRRK2 gene mutation parkinsonism undergoing either Subthalamic Nucleus (STN) or Globus Pallidus Internus (GPi) Deep-Brain stimulation (DBS): a multi-group comparison |
Disclosure: Dr. Leaver has nothing to disclose.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Expanding the NeuroChip: A low-cost and efficient diagnostic tool to detect neurological disease-related mutations |
Disclosure: Dr. Patankar has nothing to disclose.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Scopolamine Enhances Low Frequency Cortical Rhythms and Impairs Temporal Processing in the Medial Prefrontal Cortex during an Interval Timing Task |
Disclosure: Dr. Zhang has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Systemic Autoimmune Diseases and Idiopathic Epilepsy |
Disclosure: Dr. Groshans has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Mechanical Thrombectomy in patients with low NIHSS: A retrospective chart review |
Disclosure: Dr. Katyal has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | ALS/FTD-linked UBQLN2-P497H Increases K63-linked Polyubiquitinated Protein Levels |
Disclosure: Dr. Esengul has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Population Pharmacokinetics Of Lamotrigine In Adults Patients With Epilepsy. |
Disclosure: Dr. Chavez has nothing to disclose.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability |
Disclosure: Dr. Holder has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | DIRECT-DBS: A Prospective, Multi-center Clinical Study of a Directional DBS Lead – Therapeutic Windows with Directional Stimulation |
Disclosure: Dr. Steigerwald has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Boston Scientific, Medtronic, and St. Jude Medical.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Validation of an Axonal Injury Model by Scanning Electron Microscopy Imaging |
Disclosure: Dr. Wilson has nothing to disclose.
|
Behavioral and Cognitive Neurology: Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Opioid Withdrawal Shifts Amygdalar Transcriptome and is Correlated with Gut Dysbiosis |
Disclosure: Dr. O'Sullivan has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | A Case of CNS Vasculitic Changes in DRESS Syndrome |
Disclosure: Dr. Cagniart has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Experience with Endovascular Therapy in Acute Ischemic Stroke Patients Presenting with Low National Institute of Health Stroke Scale Scores |
Disclosure: Dr. Osteraas has nothing to disclose.
|
Amyotrophic Lateral Sclerosis | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | The Posttranscriptional Regulation of Ubiquilin2 by HuR in ALS Pathogenesis |
Disclosure: Dr. Lu has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Clobazam Retention Rate in Pediatric Epilepsy |
Disclosure: Dr. Gonzalez-Giraldo has nothing to disclose.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Classification of Mutations in TUBB4A: A New Spectrum of Disease |
Disclosure: Dr. Charsar has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Deep Brain stimulation in Parkinson: Use of kinematics to study impact of DBS on gait |
Disclosure: Dr. Tripathi has nothing to disclose.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Decreased PI3,5P2 and PI5P in Fibroblasts from Patients with FIG4 Deficiency |
Disclosure: Dr. Shisheva has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Brain mass dilemma- Rare presentation of ANCA negative Granulomatosis with polyangiitis |
Disclosure: Dr. Ramirez-Salazar has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Less benefits of Mechanical Thrombectomy on Acute Large Vessel Occlusion Stroke Patients Who were Transferred to a Comprehensive Stroke Center |
Disclosure: Dr. Elnazeir has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | An improved methodology for eliciting the somatosensory evoked potential of the Saphenous Nerve during the intraoperative monitoring in spine surgery |
Disclosure: Dr. Sanchez-Roldan has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Time to Onset of Efficacy in Seizure Reduction With Cenobamate (YKP3089) in Patients With Uncontrolled Partial Seizures From 2 Randomized Clinical Trials |
Disclosure: Dr. Kamin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with SK Life Science, Inc.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Spherical Nucleic Acids Show Increased Distribution and Longer Persistence than Linear Oligonucleotides in Rat Brain Following Intrathecal Administration |
Disclosure: Dr. Kandimalla has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Exicure, Inc..
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Effects of STN-DBS on axial and non-motor symptoms in patients with Parkinson’s disease: a prospective study |
Disclosure: Dr. Miguel has nothing to disclose.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Neurofilament Light Chain (NfL) Levels in CSF, Serum, and Plasma of Healthy Donors Using the Quanterix NfL Advantage Kit™ |
Disclosure: Dr. Harp has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | BDNF as a surrogate biomarker for systemic chronic damage in lupus. |
Disclosure: Dr. Alessi has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Predictors of Poor Outcome after Mechanical Thrombectomy with Successful Recanalization |
Disclosure: Dr. Anadani has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Carpal Tunnel Syndrome in Children from a Pediatric Neuromuscular Center |
Disclosure: Dr. Irumudomon has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Effects of Cenobamate on GABA-A Receptor Modulation |
Disclosure: Dr. Sharma has nothing to disclose.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Phenotypic Characterization of Individuals with SYNGAP1 Pathogenic Variants Reveals Correlation Between Posterior Dominant Rhythm and Developmental Progression |
Disclosure: Dr. Jimenez Gomez has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Long-term Effects of Bilateral Subthalamic Deep Brain Stimulation on Postural Instability and Gait Disturbance in Parkinson's Disease |
Disclosure: Dr. Shin has nothing to disclose.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | The Isoniazid Metabolites Pyridoxal Isonicotinoyl Hydrazone and Hydrazine Regulate Heme Biosynthesis |
Disclosure: Dr. Brewer has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Infliximab-induced Demyelinating Polyneuropathy in Neurosarcoidosis |
Disclosure: Dr. Lineback has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Hemorrhagic transformation after Mechanical Thrombectomy Revascularization in Large Vessel Occlusion Ischemic Stroke |
Disclosure: Dr. Saini has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Kinetics And Fiber Distribution Of The Three Muscle Heads Of Triceps For a Better C7 Myotomal EMG Study |
Disclosure: Dr. Noto has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | The Pharmacokinetics of Cenobamate in Special Populations |
Disclosure: Dr. Greene has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with SK Life Science, Inc..
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Establishing Clinical Trial Readiness of the Rett Syndrome Hand Function Measure |
Disclosure: Dr. Leonard has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Early Experiences with Multiple Independent Current Control DBS in Parkinson’s Disease |
Disclosure: Dr. Lorido has nothing to disclose.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Evaluation of apolipoprotein E and a-synuclein as potential biomarkers in CSF to monitor pharmaco-therapeutic efficacy in dopamine dictated disease states of Parkinson's disease and schizophrenia |
Disclosure: Dr. HARIPRASAD has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Movement Disorders associated with Systemic Autoimmunity: A Case Series |
Disclosure: Dr. McDonald has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Diabetes Mellitus Predicts Symptomatic Intracerebral Hemorrhage Following Thrombectomy in Acute Ischemic Stroke |
Disclosure: Dr. Montalvo Perero has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Continuous Vagus Nerve Monitoring using the Laryngeal Adductor Reflex |
Disclosure: Dr. Sanchez-Roldan has nothing to disclose.
|
Epilepsy: Antiseizure Medications I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Efficacy and Tolerability of Clobazam in Adult Drug-Refractory Epilepsy |
Disclosure: Dr. Levinson has nothing to disclose.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Resting-State EEG Abnormalities in Children with Rett Syndrome |
Disclosure: Dr. Tomlinson has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Men Are More Likely to Have DBS for Tremor in Parkinson's Disease |
Disclosure: Dr. Dalrymple has nothing to disclose.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Understand the disease emergence in hereditary transthyretin amyloidosis (hATTR): a longitudinal study of asymptomatic carriers to inaugural disease manifestations. |
Disclosure: Dr. Plante-Bordeneuve has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Skin, Gut and Nervous system – Think Degos Disease |
Disclosure: Dr. Goswami has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Higher Baseline LDL levels and Increased Hemorrhagic Risk in Ischemic Stroke Patients Undergoing Mechanical Thrombectomy |
Disclosure: Dr. Roman Casul has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Utility of Bumps Test in The Diagnosis of Carpal Tunnel Syndrome Compared to Nerve Conduction Study |
Disclosure: Dr. Ghasemi has nothing to disclose.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | JASPER Early Intervention in TSC (JETS): Methods to enhance study participation and scalability in rare disorders |
Disclosure: Dr. Jeste has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffmann-La Roche Pharmaceuticals.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Refractory Gait Freezing Following GPi Stimulation for Parkinson's Disease |
Disclosure: Dr. Sketchler has nothing to disclose.
|
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Association between LDL-C/HDL-C ratio and Hemorrhagic Transformation in Acute Ischemic Stroke Patients |
Disclosure: Dr. Wang has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Post-Malaria Neurological Syndrome |
Disclosure: Dr. Waseem has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Improved Outcomes after Mechanical Thrombectomy for In-hospital Strokes |
Disclosure: Dr. Ehab has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Hematoma Risk After Needle Electromyography (EMG) In Patients on Newer Anticoagulants |
Disclosure: Dr. Nagarajan has nothing to disclose.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Recurrent mosaic MTOR c.5930C>T (p.Thr1977Ile) Variant Causing Megalencephaly, Asymmetric Polymicrogyria, and Cutaneous Pigmentary Mosaicism |
Disclosure: Dr. Handoko has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Dorsal GPi/GPe DBS Induced Dyskinesia |
Disclosure: Dr. El Kouzi has nothing to disclose.
|
General Neurology: Rare and Unusual Presentations of Neurologic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Oromandibular dystonia in a patient with herpes simplex virus encephalitis (HSVE) |
Disclosure: Dr. Josephy has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Acute Disseminated Encephalomyelitis In An Adult Associated With Staphylococcus Aureus Bacteremia And Infective Endocarditis |
Disclosure: Dr. Shujaat has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | A Comparison of Outcomes Associated With Mechanical Thrombectomy in Acute Ischemic Stroke Patients Performed Within and Outside Clinical Trials In The United States |
Disclosure: Dr. Qureshi has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Ratio of Distal to Proximal Epidermal Nerve Fiber Density as Predictor of Small Fiber Neuropathy |
Disclosure: Dr. Farrenburg has nothing to disclose.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Iron deficiency and response to treatment with regard to sleep difficulties in Angelman Syndrome |
Disclosure: Dr. Ryan has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Outcomes of Deep Brain Stimulation Surgery in Parkinson's Disease: Real Life Experience from a Tertiary Care Center |
Disclosure: Dr. Brennan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie.
|
General Neurology: Rare and Unusual Presentations of Neurologic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Plateau waves of intracranial pressure mimicking seizure in a patient with fungal meningitis |
Disclosure: Dr. Wu has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Optic Neuritis and Spinal Nerve Root Masses- An Unusual Presentation of Neurosarcoidosis |
Disclosure: Dr. Zafar has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | The Impact of “July Phenomenon” on Door-to-Groin Time and Long-term ?Outcome of Stroke Patients Treated with Mechanical Thrombectomy |
Disclosure: Dr. Almallouhi has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders I | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Neuromuscular ultrasound for the non-invasive assessment of breast cancer patients with peripheral neuropathy from taxanes |
Disclosure: Dr. Strowd has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Innocrin Pharmaceuticals, Monteris Medical, and Novocure. Dr. Strowd has received personal compensation in an editorial capacity for Neurology. Dr. Strowd has received research support from American Society of Clinical Oncology Conquer Cancer Foundation, Southeastern Brain Tumor Foundation, and Jazz Pharmaceuticals.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | A Expanded Cohort Study of the X-linked HNRNPH2-related Neurodevelopmental Disorder |
Disclosure: Dr. Bain has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Outcomes of a Prospective, Multicenter, International Registry of Deep Brain Stimulation for Parkinson's Disease |
Disclosure: Dr. Deuschl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Boston Scientific. Dr. Deuschl has received personal compensation in an editorial capacity for European Academy of Neurology. Dr. Deuschl has received royalty, license fees, or contractual rights payments from Thieme publisher and has received research support from Medtronic and Boston Scientific.
|
General Neurology: Rare and Unusual Presentations of Neurologic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Case Report of Transient Acute Parkinsonism in the setting of West Nile Virus Encephalitis |
Disclosure: Dr. Vanguru has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | An adolescent female with angiography-negative childhood primary angiitis of the central nervous system |
Disclosure: Dr. Leung has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Mechanical Thrombectomy In Acute Ischemic Stroke: Etiology And Trends Of Readmissions In A National Population-based Cohort Study (2010-2014) |
Disclosure: Dr. Li has nothing to disclose.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Case Series: Expansion of MT-ATP6 Pathogenic Variant Phenotype |
Disclosure: Dr. Purohit has nothing to disclose.
|
Parkinson's Disease Surgical, Stem Cell and Gene Therapies | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Tradeoffs in current steering technologies for deep brain stimulation |
Disclosure: Dr. Zhang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott. Dr. Zhang has received research support from Abbott.
|
General Neurology: Rare and Unusual Presentations of Neurologic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | A Rare Case of Peripheral Neurolymphomatosis in Cutaneous T-cell Lymphoma |
Disclosure: Dr. Paul has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | Neurologic Involvement in Seronegative Sjögren’s Syndrome with Positive Lip Biopsy: A Single Center Experience |
Disclosure: Dr. Wong has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | Endovascular Thrombectomy in Acute-Onset Ischemic Stroke – Beyond the Standard Time Windows: A Case Report and a Review of the Literature |
Disclosure: Dr. So has nothing to disclose.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | Developmental and behavioral characteristics of children with Dup15q syndrome |
Disclosure: Dr. Distefano has nothing to disclose.
|
Huntington's Disease and Other Choreas | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | Salivary Biomarkers in Huntington’s Disease |
Disclosure: Dr. Corey-Bloom has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech, Teva. Dr. Corey-Bloom has received research support from Vaccinex, Wave Life Sciences, CHDI.
|
General Neurology: Rare and Unusual Presentations of Neurologic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | Neurological symptoms in a patient diagnosed with adrenal oncocytic cortical carcinoma. |
Disclosure: Dr. Aguilar Tejedor has nothing to disclose.
|
Inflammatory Neurological Complications of Systemic Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 042 | Recurrent Occipital Lobe Ischemic Strokes in COPA Syndrome |
Disclosure: Dr. Morgan has nothing to disclose.
|
Endovascular Therapy in Acute Ischemic Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 042 | Role of CT Perfusion Parameters and Collateral Score in Predicting Outcomes in Large Vessel Occlusion Strokes Who Received Both Intravenous Alteplase and Endovascular Thrombectomy |
Disclosure: Dr. Das has nothing to disclose.
|
Child Neurology: Neurogenetics | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 042 | Children with Neurogenetic Disorders Hospitalized with Community-acquired Pneumonia are at Increased Risk for Poor Outcomes |
Disclosure: Dr. Kolikonda has nothing to disclose.
|
Huntington's Disease and Other Choreas | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 042 | Preliminary Reliability and Validity of a Novel Digital Biomarker Smartphone Application to Assess Cognitive and Motor Symptoms in Huntington’s Disease (HD) |
Disclosure: Dr. Lipsmeier has received personal compensation for consulting, serving on a scientific |